Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Lyra Therapeutics, Inc. (LYRA) had Consolidated Net Income/Loss of $-93.44M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$1.53M |
|
$-93.44M |
|
-- |
|
$1.53M |
|
$97.88M |
|
$-96.35M |
|
$2.95M |
|
$-93.40M |
|
$-93.40M |
|
$-93.44M |
|
$-93.44M |
|
|
Consolidated Net Income/Loss |
$-93.44M |
$-93.44M |
|
$-96.35M |
|
$-98.15M |
|
1.30M |
|
1.30M |
|
$-71.50 |
|
$-71.50 |
|
| Balance Sheet Financials | |
$43.02M |
|
$1.40M |
|
$23.32M |
|
$66.35M |
|
$12.63M |
|
-- |
|
$42.12M |
|
$54.75M |
|
$11.59M |
|
$11.59M |
|
$11.59M |
|
1.31M |
|
| Cash Flow Statement Financials | |
$-70.01M |
|
$80.31M |
|
$8.53M |
|
$23.75M |
|
$42.57M |
|
$18.82M |
|
$6.72M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.41 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-6280.83% |
|
-6280.83% |
|
-6398.50% |
|
-6088.40% |
|
-6090.94% |
|
$-72.35M |
|
-- |
|
-- |
|
-- |
|
0.02 |
|
-- |
|
-- |
|
-- |
|
-805.89% |
|
-805.89% |
|
-140.83% |
|
-805.89% |
|
$8.85 |
|
$-55.56 |
|
$-53.76 |
|